You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 3
  • 260 Impact of BRCA & PD-L1 in EOC patients receiving standard 1st line therapy +/- Pembrolizumab: Exploratory analyses from the NeoPembrOV Study (GINECO)

Article metrics

Article menu

Download PDFPDF

Ovarian cancer
260 Impact of BRCA & PD-L1 in EOC patients receiving standard 1st line therapy +/- Pembrolizumab: Exploratory analyses from the NeoPembrOV Study (GINECO)
Free

 

Online download statistics by month:

Online download statistics by month: October 2021 to May 2023

AbstractFullPdf
Oct 20215308
Nov 202157010
Dec 20211006
Jan 20225104
Feb 20221701
Mar 20222304
Apr 20222405
May 202224012
Jun 20221805
Jul 20221704
Aug 20223007
Sep 20222709
Oct 202214015
Nov 20221403
Dec 20222804
Jan 20233407
Feb 20232001
Mar 2023600
Apr 202322015
May 20231000
Total4990120